Skip to main content
SpringerLink
Log in

Kombinationen mit Psychopharmaka in der Behandlung von Angst- und Zwangsstörungen

  • Chapter
  • First Online:
Polypharmazie in der Behandlung psychischer Erkrankungen

  • 2416 Accesses

Zusammenfassung

Neuere Untersuchungen zeigen, dass Angststörungen die häufigsten psychiatrischen Erkrankungen überhaupt sind, so leiden ca. 15 bis 20% aller Patienten, die sich bei einem Allgemeinarzt vorstellen, an einer Angststörung. Bei der Pharmakotherapie dieser Störungen zeigt – ähnlich wie bei der Depression – ca. 1/3 der Patienten kein genügendes Ansprechen. Hier werden häufig Kombinationstherapien angewandt. Der vorliegende Beitrag fasst die hierzu vorliegenden Studien zusammen. Am besten ist die Hinzugabe eines atypischen Antipsychotikums (z. B. Risperidon) zu einer bestehenden SSRI-Therapie bei der Zwangsstörung gezeigt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Aboujaoude E, Barry JJ, Gamel N (2009) Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29: 51–55

    Article  CAS  PubMed  Google Scholar 

  • Agid O, Lerer B (1999) Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiaty 60: 55–56

    Article  CAS  Google Scholar 

  • Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D (2006) Quetiapine as an adjucntive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol 21: 29–33

    Article  PubMed  Google Scholar 

  • Ak M, Bulut SD, Bozkurt A, Ozsahin A (2011) Aripiprazol augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther 28: 341–348

    Article  CAS  PubMed  Google Scholar 

  • Altamura AC, Serati M, Buoli M, Dell`Osso B (2011) Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol 26: 201–205

    Article  PubMed  Google Scholar 

  • D´Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R, La Torre D, D`Arrigo C, Spina E (2003) Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 27: 619–623

    Article  CAS  Google Scholar 

  • Ashton AK (2005) Aripiprazole augmentation of combination escitalopram and sertraline in the treatment of refractory obsessive-compulsive disorder. Psychiatry 2: 18

    Google Scholar 

  • Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002) Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17: 115–119

    Article  CAS  PubMed  Google Scholar 

  • Bandelow B, Rüther E (2004) Treatment-resistant panic disorder. CNS Spectrums 9: 725–739

    Article  PubMed  Google Scholar 

  • Bartzokis G, Freeman T, Roca V, Kimbrell T, Brown SJ, Lu PH, Turner J, Mintz J, Saunders S (2003) Risperidone in the treatment of chronic combat-related posttraumatic stress disorder [Abstract]. Biol Psychiatry 53: 135S

    Article  Google Scholar 

  • Baxter LR, Li X, Jackson WT, May RS, Tolbert LC (2002) Adjunctive risperidone in the treatment of SSRI-refractory obsessive-compulsive disorder. Presented at the Society of Biological Psychiatry Annual Meeting, Philadelphia

    Google Scholar 

  • Berlant JL (2004) Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 18: 24

    Article  CAS  Google Scholar 

  • Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E (2011) Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 72: 716–721

    Article  PubMed  CAS  Google Scholar 

  • Blier P (2001) Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 62 (Suppl 4): 7–11

    CAS  PubMed  Google Scholar 

  • Blier P, Bergeron R (1996) Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 11: 37–44

    Article  CAS  PubMed  Google Scholar 

  • Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric C, Bracken MB, Leckmann JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11: 622–632

    Article  CAS  PubMed  Google Scholar 

  • Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A (2005) Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 66: 73–79

    Article  CAS  PubMed  Google Scholar 

  • Bogetto F, Bellino S, Vaschetto P, Ziero S (2000) Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 96: 91–98

    Article  CAS  PubMed  Google Scholar 

  • Brawman-Mintzer O, Knapp R, Nietert P (2005) Adjunctive risperidone in generzalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 66: 1321–1325

    Article  CAS  PubMed  Google Scholar 

  • Bruno A, Micó U, Padndolfo G, Mallamace D, Abenavoli E, Di Nardo F, D`Arrigo C, Spina E, Zoccali RA, Muscatello MR (2012) Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 26: 1456–1463

    Article  PubMed  Google Scholar 

  • Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E (2006) Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology 53: 157–168

    Article  PubMed  Google Scholar 

  • Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidmant KM, Saxena S (2004) Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 65: 565–568

    Article  CAS  PubMed  Google Scholar 

  • Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study (ISRCTN83050762]. BMC Psychiatry 5: 5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Carey PD, Lochner C, Kidd M, Van Ameringen M, Stein DJ, Denys D (2012) Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable? Int Clin Psychopharmacol 27: 321–325

    PubMed  Google Scholar 

  • Chao IL (2004) Olanzapine augmentation in panic disorder [Letter]. Pharmacopsychiatry 37: 239–240

    Article  CAS  PubMed  Google Scholar 

  • Cohen LS (2003) Quetiapine in treatment resistant obsessive-compulsive disorder [letter]. J Am Acad Child Adolesc Psychiatry 42: 623–624

    Article  PubMed  Google Scholar 

  • Cora-Locatelli G, Greenberg BD, Martin J, Murphy D (1998) Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry 59 (Suppl 9): 480–481

    Article  CAS  PubMed  Google Scholar 

  • Crane DL (2005) Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders. CNS Spectr 10: 176–179

    Article  PubMed  Google Scholar 

  • Crockett BA, Churchilli E, Davidson JRT (2004) A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry 16: 127–132

    Article  PubMed  Google Scholar 

  • Dannon PN, Iancu I, Grunhaus LJ (1999) Short-term potentiation of paroxetine with clonazepam in the treatment of patients with panic disorder [abstract, pp 153]. APA, Washington, D.C.

    Google Scholar 

  • Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J (2000) Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 10: 165–169

    Article  CAS  PubMed  Google Scholar 

  • da Rocca FF, Correa H (2007) Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Progr Neuro-Psychopharmacol Biol Psychiatry 31: 1550–1551

    Article  Google Scholar 

  • David D, DeFaria L, Mellan TA (2006) Adjunctive risperidone treatment in combat veterans with chronic PTSD. Depress Anx 23: 489–491

    Article  CAS  Google Scholar 

  • Delgado PL, Goodman WK, Price LH, Heninger GR, Charney DS (1990) Fluvoxamine/pimozide treatment of concurrent Tourette`s and obsessive-compulsive disorder. Br J Psychiatry 157: 762–765

    Article  CAS  PubMed  Google Scholar 

  • Dell`Osso B, Mundo E, Altamura AC (2006) Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series. CNS Spectr 11: 879–883

    Article  PubMed  Google Scholar 

  • Denys D, van Megen H, Westenberg H (2002) Quetiapine addition to serotonin reuptake inhibitor treatment in pateints with treatment-refractory obsessive-compulsive disorder. An open-label study. J Clin Psychiatry 63: 700–703

    Article  CAS  PubMed  Google Scholar 

  • Denys D, de Gues F, van Mengen HJGM, Westenberg HGM (2004) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65: 1040–1048

    Article  CAS  PubMed  Google Scholar 

  • Denys D, Fineberg N, Carey PD, Stein DJ (2007) Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors. Biol Psychiatry 61: 412–414

    Article  CAS  PubMed  Google Scholar 

  • Di Nicola M, Tedeschi D, Martinotti G, De Vita O, Monetta M, Pozzi G, Janiri L (2011) Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol 31: 675–677

    Article  PubMed  Google Scholar 

  • Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC (2011) A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 31: 763–768

    Article  CAS  PubMed  Google Scholar 

  • Dold M, Aigner M, Lanzenberger R, Kasper S (2011) Effektivität einer Augmentationstherapie mit Antipsychotika bei therapie-resistenten Zwangsstörungen – eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien. Fortschr Neurol Psychiatr 79: 453–466

    Article  CAS  PubMed  Google Scholar 

  • Eppel AB (1989) Imipramine and clonazepam for panic disorder. Am J Psychiatry 146: 283

    Article  CAS  PubMed  Google Scholar 

  • Erzegovesi S, Gulielmo E, Siliprandi F, Bellodi L (2005) Low-dose risperidone augmentation of fluvoxamine treatment in obesessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 15: 69–74

    Article  CAS  PubMed  Google Scholar 

  • Etxebeste M, Aragüés E, Malo P, Pacheco L (2000) Olanzapine and panic attacks. Am J Psychiatry 157: 659–660

    Article  CAS  PubMed  Google Scholar 

  • Figuero Y, Rosenberg DR, Birmaher B, Keshavan MS (1998) Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 8: 61–67

    Article  Google Scholar 

  • Filteau MJ, Leblanc J, Bouchard RH (2003) Quetiapine reduces flashbacks in chronic posttraumatic stress disorder [letter]. Can J Psychiatry 48: 282–283

    PubMed  Google Scholar 

  • Fineberg NA, Sivakumaran T, Roberts A, Gale T (2005) Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 20: 223–226

    Article  PubMed  Google Scholar 

  • Fineberg NA, Gale TM, Sivakumaran T (2006a) A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol 20: 97–103

    Article  CAS  PubMed  Google Scholar 

  • Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, Seedat S, Westenberg H, Denys D (2006b) Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 21: 337–343

    Article  PubMed  Google Scholar 

  • Fitzgerald KD, Stewart CM, Tawille V, Rosenberg DR (1999) Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 9: 115–123

    Article  CAS  PubMed  Google Scholar 

  • Fontenelle LF, Mendlowicz MV, Miguel EC, Versiani M (2005) Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. Word J Biol Psychiatry 6: 57–59

    Article  Google Scholar 

  • Francobandiera G (2001) Olanzapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 46: 356–358

    Article  CAS  PubMed  Google Scholar 

  • Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi JD (2007) Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder [letter]. J Clin Psychiatry 68: 972–973

    Article  PubMed  Google Scholar 

  • Fux M, Benjamin J, Belmaker RH (1999) Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: A double-blind cross-over study. In J Neuropsychopharmacol 2: 193–195

    Article  CAS  Google Scholar 

  • Gabriel A (2011) The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study. Clin Ther 162: 113–118

    CAS  Google Scholar 

  • Gastfriend D, Rosenbaum J (1989) Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. Am J Psychiatry 146: 914–916

    Article  CAS  PubMed  Google Scholar 

  • Goddard AW, Brouette T, Almai A, Jetty P, Ciary C, Woods S, Charney D (2001) Early co-administration of clonazepam with sertralin: a safe, rapidly acting treatment for panic disorder. Arch Gen Psychiatry 58: 681–686

    Article  CAS  PubMed  Google Scholar 

  • Goldstein S (1986) Sequential treatment of panic disorder with alprazolam and imipramine. Am J Psychiatry 143: 1634

    Article  CAS  PubMed  Google Scholar 

  • Grady T, Pigott TA, L´Heureux F, Hill J, Bernstein L, Murphy D (1993) A double-blind study of adjuvant buspirone hydrochloride in fluoxetine-treated patients with OCD. Am J Psychiatry 150: 819–821

    Article  CAS  PubMed  Google Scholar 

  • Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP (2002) Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 23: 15–20

    Article  Google Scholar 

  • Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW (2003) Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 18: 1–8

    Article  CAS  PubMed  Google Scholar 

  • Harada T, Yamada K, Sakamoto K, Ishigooka J (2009) Aripiprazole augmentation for a patient with partial remission of panic disorder. J Clin Psychopharmacol 29: 301–302

    Article  PubMed  Google Scholar 

  • Heresco-Levy U, Vass A, Bloch, Wolosker H, Dumin E, Balan L, Deutsch L, Kremer I (2009) Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 12: 1275–1282

    Google Scholar 

  • Higuma H, Kanehisa M, Maruyama Y, Ishitobi Y, Tanaka Y, Tsuru J, Hanada H, Kodama K, Isogawa K, Akiyoshi J (2012) Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series. World J Biol Psychiatry 13: 14–21

    Article  PubMed  Google Scholar 

  • Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 20: 556–559

    Article  CAS  PubMed  Google Scholar 

  • Hollander E, Baldini Ross N, Sood E, Pallanti S (2003) Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 6: 397–401

    Article  CAS  PubMed  Google Scholar 

  • Hollander E, Dell`Osso B (2006) Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 21: 189–191

    Article  PubMed  Google Scholar 

  • Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ (2006) Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev Oct 18; (4): CD005473

    Google Scholar 

  • Iwata Y, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N (2000) Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. J Clin Psychiatry 61: 528–529

    Article  CAS  PubMed  Google Scholar 

  • Jakovljević M, Šagud M, Mihaljević-Peleš A (2003) Olanzapine in the treatment-resistant combat-related PTSD – a series of case reports. Acta Psychiatr Sand 107: 394–396

    Article  Google Scholar 

  • Jenike MA, Baer L, Buttolph L (1991) Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1: 13–14

    Google Scholar 

  • Karaiskos D, Pappa D, Tzavellas E, Siarkos K, Katirtzoglou E, Papadimitriou GN, Politis A (2013) Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder – an open-label study. Int J Geriatr Psychiatry 28: 100–105

    Article  PubMed  Google Scholar 

  • Kasper S (2007) Neurotische, Belastungs- und somatoforme Störungen. In: Kasper S, Volz HP (Hrsg): Psychiatrie compact, Thieme, Stuttgart, S. 141–179

    Google Scholar 

  • Kazzelnick DJ, Saidi J, Vanelli MR, Jefferson JW, Harper JM, McCrary KE (2006) Time to response in panic disorder in a naturalistic setting: Combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry 3: 39–49

    Google Scholar 

  • Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A (2008) Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 22: 1480–1486

    Article  CAS  PubMed  Google Scholar 

  • Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA, Smith HM (1993) Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology 27: 150–153

    Article  PubMed  Google Scholar 

  • Khaldi S, Kornreich C, Dan B, Pelc I (2003) Usefulness of olanzapine in refractory panic patients. J Clin Psychopharmacol 23: 100–101

    Article  PubMed  Google Scholar 

  • Koran LM, Ringold AL, Elliot MA (2000) Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 61 (Suppl 7): 514–517

    Article  CAS  PubMed  Google Scholar 

  • Koran LM, Aboujaoude E, Gamel NN (2009) Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 70: 1530–1535

    Article  CAS  PubMed  Google Scholar 

  • Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F (2008) Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 28: 550–554

    Article  CAS  PubMed  Google Scholar 

  • Leonard HL, Topol D, Burkstein O, Hindmarsh D, Allen AJ, Swedo SE (1994) Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 33: 792–794

    Article  CAS  PubMed  Google Scholar 

  • Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR (2005) Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a cross-over study. J Clin Psychiatry 66: 736–743

    Article  CAS  PubMed  Google Scholar 

  • Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A (2003) Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of reported cases. Progr Neuro-Psychopharmacol Biol Psychiatry 27: 333–346

    Article  Google Scholar 

  • Mahboub N, Asemota B, Alexopoulos GS (2011) The effect of riluzole augmentation in a patient with treatment-resistant obsessive-compulsive disorder, taking two other glutamatergic agents. J Neuropsychiatry Clin Neurosci 23: E24–E25

    Google Scholar 

  • Maina G, Albert U, Ziero S, Bogetto F (2003) Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol 18: 23–28

    Article  PubMed  Google Scholar 

  • Mancini C, van Ameringen M, Farvolden P (2002) Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder? J Affect Dis 68: 59–65

    Article  CAS  PubMed  Google Scholar 

  • Marazitti D, Pallanti S (1999) Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 156: 1834–1835

    Google Scholar 

  • Marazziti D, Pfanner C, Dell`Osso B, Ciapparelli A, Presta S, Corretti G, Di Nasso E, Mungai F, Dell`Osso L (2005) Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian ling-term open-label study. J Psychopharmacol 19: 392–394

    Article  CAS  PubMed  Google Scholar 

  • Markovitz PJ, Stagno SJ, Calabrese JR (1990) Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 147: 798–800

    Article  CAS  PubMed  Google Scholar 

  • Masi G, Pfanner C, Millepiedi S, Berloffa S (2010) Aripirprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 30: 688–693

    Article  CAS  PubMed  Google Scholar 

  • Masdrakis VG, Papadimitriou GN, Oulis P (2010) Lamotrigine administration in panic disorder with agoraphobia. Clin Neuropharmacol 33: 126–128

    Article  PubMed  Google Scholar 

  • Matsunaga H, Hayashida K, Maebayashi K, Mito H, Kiriike N (2011) A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder. Int J Psychiatry Clin Pract 15: 263–269

    Article  CAS  PubMed  Google Scholar 

  • Mattes JA (1986) A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1: 170–173

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR (1990) Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147: 652–654

    Article  CAS  PubMed  Google Scholar 

  • McDougle C, Price L, Goodman W, Charney D, Heninger G (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder. J Clin Psychopharmacol 11: 175–184

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51: 302–308

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH (1995) Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 56: 527–528

    Google Scholar 

  • McDougle CJ, Eppersen CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitory-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57: 794–801

    Article  CAS  PubMed  Google Scholar 

  • Menza MA, Dobkin RD, Marin H (2007) An open-label trial of aripiprazol for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 27: 207–210

    Article  PubMed  Google Scholar 

  • Misri S, Milis L (2004) Obsessive-compulsive disorder in the postpartum. Open-label trial of quetiapine augmentation. J Clin Psychopharmacol 24: 624–627

    Article  CAS  PubMed  Google Scholar 

  • Mohr N, Vythilingum B, Ernsley RA, Stein DJ (2002) Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 17: 37–40

    Article  CAS  PubMed  Google Scholar 

  • Monnelly E, Ciraulo DA, Knapp C, Keane TM (2003) Low dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 23: 193–196

    Article  CAS  PubMed  Google Scholar 

  • Mundo E, Guglielmo E, Bellodi L (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int J Psychopharmacol 13: 219–224

    Article  CAS  Google Scholar 

  • Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 31: 174–179

    Article  CAS  PubMed  Google Scholar 

  • Noorbala AA, Hosseini SH, Mohammadi MR, Akhondzadeh S (1998) Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. J Clin Pharm Ther 23: 155–159

    Article  CAS  PubMed  Google Scholar 

  • Ontiveros A, Fontaine R (1992) Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 17: 78–80

    CAS  PubMed  PubMed Central  Google Scholar 

  • Oshimo T, Ohta M, Ueno R, Hashimoto T, Shirakawa O, Maeda K (2003) Effects of combined use of serotonin reuptake inhibitor and risperidone for obsessive-compulsive disorders [abstract]. Int Clin Psychopharmacol 18: 185

    Article  Google Scholar 

  • Oulis P, Masdrakis VG, Karapoulios E, Krakatsanis NA, Kouzoupis AV, Kontantakopoulos G, Soldatos CR (2008) Pregabalin augmentation to sertraline-risperidone combination in the treatment of obsessive-compulsive disorder. Prim Care Companion J Clin Psychiatry 10: 249

    Article  PubMed  PubMed Central  Google Scholar 

  • Oulis P, Masdrakis VG, Karapoulios E, Karakatsanis NA, Kouzoupis AV, Konstantakopoulos G, Soldatos CR (2009) Tiagebine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder. World J Biol Psychiatry 10: 953–955

    Article  PubMed  Google Scholar 

  • Oulis P, Mourikis I, Konstantakopoulos G (2011) Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 26: 221–224

    Article  PubMed  Google Scholar 

  • Pae CU, Marks DM, Han C, Masand PS, Patkar AA (2009) Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol 24: 29–33

    Article  PubMed  Google Scholar 

  • Pallanti S, Quercioli L, Paiva RS, Koran LM (1999) Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 14: 101–106

    Article  CAS  PubMed  Google Scholar 

  • Pallanti S, Quercioli L, Bruscoli M (2004) Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: A pilot study. J Clin Psychiatry 65: 1394–1399

    Article  CAS  PubMed  Google Scholar 

  • Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E (2009) Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 23: 1047–1055

    Article  CAS  PubMed  Google Scholar 

  • Pasquini M, Biondi M (2006) Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30: 1173–1175

    Article  CAS  PubMed  Google Scholar 

  • Pasquini M, Berardelli I, Biondi M (2010) Amantadine augmentation for refractory obsessive-compulsive disorder: a case report. J Clin Psychpharmacol 30: 85–86

    Article  Google Scholar 

  • Pessina E, Albert U, Bogetto F, Maina G (2009) Aripiprazol augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 24: 265–269

    Article  PubMed  Google Scholar 

  • Pfanner C, Marazziti D, Dell`Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB (2000) Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 15: 297–301

    Article  CAS  PubMed  Google Scholar 

  • Pigott TA, L`Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL (1992) A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 11–18

    CAS  PubMed  Google Scholar 

  • Pitchot W, Ansseau M (2012) Efficacy of quetiapine in treatment-resistant panic disorder: a case report. Asian J Psychiatr 5: 204–205

    Article  PubMed  Google Scholar 

  • Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V (2008) Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol 28: 363–367

    Article  PubMed  Google Scholar 

  • Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW (2003) Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17: 276–282

    Article  CAS  PubMed  Google Scholar 

  • Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J (2006) Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo-controlled study. Biol Psychiatry 59: 211–215

    Article  CAS  PubMed  Google Scholar 

  • Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R (2008). Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 65: 551–562

    Article  CAS  PubMed  Google Scholar 

  • Poyurovsky M, Weizman R, Weizman A, Koran L (2005) Memantine for treatment-resistant OCD [letter]. Am J Psychiatry 162: 2191–2192

    Article  PubMed  Google Scholar 

  • Presecki P, Mihanović M, Silić A, Vuina AL, Caratan S (2010) Venlafaxine-quetiapine combination in the treatment of complicated clinical picture of enduring personality changes following PTSD in comorbidity with psychotic depression. Psychiatr Danub 22: 360–362

    PubMed  Google Scholar 

  • Rapaport MH, Skarky SB, Katzelnick DJ, DeWester JN, Harper JM, McCrary KE (2006) Time to response in generalized anxiety disorder in a naturalistic setting: Combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry 3: 50–59

    PubMed  PubMed Central  Google Scholar 

  • Rasmussen S (1984) Lithium and tryptophan augmentation in clomipramine-resistant OCD. Am J Psychiatry 141: 1283–1285

    Article  CAS  PubMed  Google Scholar 

  • Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996) Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 32: 677–682

    CAS  PubMed  Google Scholar 

  • Richardson JD, Fikretoglu D, Liu A, McIntosh D (2011) Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. BMC Psychiatry 11: 86

    Article  PubMed  PubMed Central  Google Scholar 

  • Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ (2012) Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI therapy. Int Clin Psychopharmacol 27: 142–150

    Article  PubMed  Google Scholar 

  • Riddle MA, Leckman JF, Hardin MT, Anderson GM, Cohen DJ (1988) Fluoxetine treatment of obsessions and compulsions in patients with Tourette`s syndrome [letter]. Am J Psychiatry 145: 1173–1174

    CAS  PubMed  Google Scholar 

  • Rodiguez CI, Bender J Jr, Marcus SM, Snape M, Rynn M, Simpson HB (2010) Monocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J Clin Psychiatry 71: 1247–1249

    Article  Google Scholar 

  • Rubio G, Jiménez-Arriero MA, Martínez-Gras I, Manzanares J, Palomo T (2006) The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Ciin Psychopharmacol 26: 341–334

    Article  Google Scholar 

  • Saito M, Miyaoka H (2007) Augmentation of paroxetine with clocapramine in panic disorder [letter]. Psychiatry Clin Neurosci 61: 449

    Article  PubMed  Google Scholar 

  • Sareen J, Kirshner A, Lander M, Kjernisted KD, Eleff MK, Reiss JP (2004) Do antipsychotics ameliorate or exacerbate Obsessive-Compulsive Disorder symptoms? A systematic review. J Affect Disord 82: 167–174

    Article  CAS  PubMed  Google Scholar 

  • Sarkar R, Klein J, Krüger S (2008) Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology 197: 687–688

    Article  CAS  PubMed  Google Scholar 

  • Sattar SP, Ucci B, Grant K, Bhatia SC, Petty F (2002) Quetiapine therapy for posttraumatic stress disorder. Ann Pharmacother 36: 1875–1878

    Article  PubMed  Google Scholar 

  • Saxena S, Wang D, Bystritsky A, Baxter LR (1996) Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 57: 303–306

    CAS  PubMed  Google Scholar 

  • Sayyah M, Boostani H, Pakseresht S, Malayeri A (2011) A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res 189: 403–406

    Article  CAS  PubMed  Google Scholar 

  • Sayyah M, Olapour A, Saeedabad Ys, Yazdan Parast R, Malayeri A (2012a) Evaluation of oral zinc sulfate on obsessive-compulsive disorder: a randomized placebo-controlled trial. Nutrition 28: 892–895

    Article  CAS  PubMed  Google Scholar 

  • Sayyah M, Saayah M, Boostani HI, Ghaffari SM, Hoseini A (2012b) Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety 29: 850–854

    Article  CAS  PubMed  Google Scholar 

  • Schutters SI, van Megen HJ, Van Veen JF, Schruers KR, Westenberg HG (2011) Paroxetine augmentation in patients with generalized social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol 26: 72–76

    Article  CAS  PubMed  Google Scholar 

  • Seedat S, Stein MB (2004) Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 65: 244–248

    CAS  PubMed  Google Scholar 

  • Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O (2011) The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol 26: 51–57

    Article  CAS  PubMed  Google Scholar 

  • Sepede G, De Beradis D, Gambi F, Campanella D, La Rovere R, D`Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM (2006) Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 26: 45–49

    Article  CAS  PubMed  Google Scholar 

  • Shad MU, Suris AM, North CS (2011) Novel combination strategy to optimize treatment for PTSD. Hum Psychopharmacol 26: 4–11

    Article  CAS  PubMed  Google Scholar 

  • Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MCK, Blier P, Goodman WK (2004) A double-blind, placebo-controlled trial of olanzapine addition to fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 55: 553–555

    Article  CAS  PubMed  Google Scholar 

  • Simon NM, Safren SA, Otto MW, Sharma SG, Lanka GD, Pollack MH (2002) Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorders. J Affect Dis 69: 33–34

    Google Scholar 

  • Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ 3rd, Zhang W, Davidson JR, Pollack MH (2008) Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 197: 675–681

    Article  CAS  Google Scholar 

  • Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I (2010) A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol 25: 509–513

    Article  CAS  PubMed  Google Scholar 

  • States JH, St. Dennis CK (2003) Chronic sleep disruption and the reexperiencing cluster of posttraumatic stress disorder symptoms are improved by olanzapine: Brief review of the literature and a case-based series. J Clin Psychiatry 5: 74–79

    Google Scholar 

  • Stein MB, Sareen J, Hami S, Chao J (2001) Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, cross-over study. Am J Psychiatry 158; 1725–1727

    Google Scholar 

  • Stein MB, Kline NA, Matloff JL (2002) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry 159: 1777–1779

    Article  PubMed  Google Scholar 

  • Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK (2008) Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anx 25: 172–174

    Article  CAS  Google Scholar 

  • Tiffon L, Coplan JJD, Papp LA, Gorman JM (1994) Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry 55: 66–69

    CAS  PubMed  Google Scholar 

  • Uhlenhuth EH, Balter MB, Ban TA, Yang K (1998) International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: V. Treatment strategies in panic disorder, 1992–1997. J Clin Psychopharmacol 18 (Suppl 2): 27S–31S

    Article  CAS  PubMed  Google Scholar 

  • Uzun O (2010) Lamotrigin as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case-report. J Psychopharmacol 24: 425–427

    Article  CAS  PubMed  Google Scholar 

  • Van Ameringen M, Mancini C, Wilson C (1996) Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 39: 115–121

    Article  PubMed  Google Scholar 

  • Van Ameringen M, Mancini C, Patterson B, Bennett M (2006) Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 23: 1–5

    Article  PubMed  CAS  Google Scholar 

  • Weiss EL, Potenza MN, McDougle CJ, Epperson CN (1999) Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 60: 524–527

    Article  CAS  PubMed  Google Scholar 

  • Woods SW, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS (1992) Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol 12: 32–38

    Article  CAS  PubMed  Google Scholar 

  • Yoshimura R, Kaneko S, Shinkai K, Nakamura J (2006) Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci 60: 389–393

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin, Schloss Werneck, Balthasar-Neumann-Platz 1, 97440, Werneck, Deutschland

    Prof. Dr. med. Hans-Peter Volz

Authors
  1. Prof. Dr. med. Hans-Peter Volz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Peter Volz .

Editor information

Editors and Affiliations

  1. Danuvius Klinik Pfaffenhofen, Pfaffenhofen, Germany

    Thomas Messer

  2. und Psychosomatik, Bezirkskrankenhaus Augsburg Klinik für Psychiatrie, Psychotherapie,, Augsburg, Germany

    Max Schmauß

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Wien

About this chapter

Cite this chapter

Volz, HP. (2016). Kombinationen mit Psychopharmaka in der Behandlung von Angst- und Zwangsstörungen. In: Messer, T., Schmauß, M. (eds) Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1849-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1849-8_8

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1848-1

  • Online ISBN: 978-3-7091-1849-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation